Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) EBT (2019 - 2025)

Bioadaptives' EBT history spans 7 years, with the latest figure at -$823346.0 for Q4 2025.

  • Quarterly results put EBT at -$823346.0 for Q4 2025, down 121.46% from a year ago — trailing twelve months through Dec 2025 was -$1.6 million (down 148.01% YoY), and the annual figure for FY2025 was -$1.6 million, down 73.26%.
  • EBT for Q4 2025 was -$823346.0 at Bioadaptives, down from -$379502.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $19095.0 in Q4 2023 to a low of -$823346.0 in Q4 2025.
  • The 5-year median for EBT is -$177084.0 (2022), against an average of -$223249.4.
  • The sharpest move saw EBT surged 106.86% in 2023, then plummeted 2047.04% in 2024.
  • Year by year, EBT stood at -$89602.0 in 2021, then plummeted by 210.84% to -$278520.0 in 2022, then surged by 106.86% to $19095.0 in 2023, then plummeted by 2047.04% to -$371788.0 in 2024, then plummeted by 121.46% to -$823346.0 in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$823346.0, -$379502.0, and -$157914.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.